Corey Fishman
CEO and Founder of Iterum Therapeutics
Articles
SURE1 and REASSURE Trials Paved Way for FDA Approval of Orlynvah
October 30th 2024Corey Fishman and Steven Aronin, MD, discussed trial highlights of Orlynvah for uncomplicated urinary tract infections and outlining plans to seek partners for a market launch to address antibiotic resistance and enhance patient treatment options.
Read More
FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract Infections
Published: October 29th 2024 | Updated: October 29th 2024Iterum Therapeutics receives approval for Orlynvah as the first oral penem for treating uncomplicated urinary tract infections in adult women with limited treatment options.
Read More
Latest Updated Articles
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: November 10th 2024 | Updated: November 21st 2024
STAY PrEPARED: Understanding COVID-19 Pre-Exposure Prophylaxis
Published: November 18th 2024 | Updated: November 18th 2024
Echinocandin Dosing Considerations in Obese Patients: A Review
Published: November 17th 2024 | Updated: November 21st 2024
More Women Than Men Die After Staph Bacteremia
Published: November 14th 2024 | Updated: November 21st 2024
Considerations for Discharge
Published: November 13th 2024 | Updated: November 21st 2024
Efficacy of 8-Week Daclatasvir-Sofosbuvir Regimen for Chronic Hepatitis C
